Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase 1/2 4

Status

Completed 5Withdrawn 1

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 6

Interventions

Prednisone 53Radiotherapy 52Docetaxel 51Leuprolide 48Goserelin 47bicalutamide 45enzalutamide 28acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27Androgen Antagonists 27Flutamide 24Triptorelin Pamoate 22apalutamide 18Gonadotropin-Releasing Hormone 18Abiraterone Acetate 17Radiation 15abiraterone 14Zoledronic Acid 14Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 12Prednisolone 11luprolide acetate gel depot 10darolutamide 9Radiosurgery 9cabazitaxel 8Standard of Care 8Specimen Handling 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Estramustine 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Neoplasms × orteronel × Clear all
NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
239 enrolled 38 charts
Genitourinary

Prostatic Neoplasms

NCT01809691 2025-12-31

S1216

SWOG Cancer Research Network

Phase 3 Completed
1,313 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

NCT01707966 2019-05-15

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Swiss Cancer Institute

Phase 3 Completed
47 enrolled
Genitourinary

Prostatic Neoplasms

NCT01193257 2018-12-19

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

Takeda

Phase 3 Completed
1,099 enrolled 32 charts
Genitourinary

Prostatic Neoplasms

NCT02053311 2018-07-30

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Swiss Cancer Institute

Phase 3 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT01193244 2017-05-17

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Takeda

Phase 3 Completed
1,560 enrolled 35 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡